BioCentury
ARTICLE | Company News

DNDN gains GERN cancer technology

October 23, 2001 7:00 AM UTC

Geron (GERN) non-exclusively licensed its telomerase cancer immunotherapy technology to Dendreon (DNDN). DNDN will use the telomerase as an antigen in a vaccine to induce an immune response against ma...